Loading
Obesity (BMI>30) / Insulin Resistance / Obesity (BMI > 35) · Observational Study
ClinicalTrials.gov · August 19, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed retrospective observational cohort study registered to examine serum FABP4 dynamics and its association with weight loss and systemic inflammation after Roux-en-Y gastric bypass in 28 adults. No results are posted in this registry record; the study remains preliminary pending outcome reporting.
Observational. Obesity (BMI>30), Obesity (BMI > 35), Insulin Resistance, Bariatric Surgery, Bariatric Surgery (Gastric Bypass); age from 18 Years; to 65 Years. Intervention: Group/Cohort Label: FABP4 Responders; Group/Cohort Label: FABP4 Rebound/Non-responders. n = 28.
This is a completed retrospective observational cohort study registered to examine serum FABP4 dynamics and its association with weight loss and systemic inflammation after Roux-en-Y gastric bypass in 28 adults. No results are posted in this registry record; the study remains preliminary pending outcome reporting.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Results could clarify whether FABP4 response patterns predict weight loss success and inflammation reduction after bariatric surgery, potentially informing patient stratification or monitoring. Conclusions cannot be drawn until results are published.
Retrospective observational cohort study with small sample size (n=28) and no published results reported in this registry record; recruitment completed but outcomes not yet disclosed.
As stated by the source record.
Quoted from the source exactly as published.
Results could clarify whether FABP4 response patterns predict weight loss success and inflammation reduction after bariatric surgery, potentially informing patient stratification or monitoring. Conclusions cannot be drawn until results are published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07774208). This is a study registration, not published results. Lead sponsor: Istanbul University. Recruitment status: COMPLETED. Study type: OBSERVATIONAL. Enrollment: 28 participants (ACTUAL). Conditions: Obesity (BMI>30), Obesity (BMI > 35), Insulin Resistance, Bariatric Surgery, Bariatric Surgery (Gastric Bypass). Primary outcome measures: Measure: Change in serum FABP4 level from baseline to 6 months after RYGB , Time Frame: Baseline, 3 months, 6 months. Brief summary: This retrospective observational cohort study examined serum fatty acid-binding protein 4 (FABP4) dynamics in 28 adults who underwent Roux-en-Y gastric bypass (RYGB), followed at baseline, 3 months, and 6 months. Anthropometric, metabolic, and inflammatory parameters were assessed alongside FABP4, fasting GLP-1, and PYY. Patients were classified as FABP4 responders (decrease from baseline to 6 months) or rebound/non-responders. The study investigated whether FABP4 trajectory after RYGB is associated with the magnitude of weight loss, systemic inflammation, and fasting incretin change.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.